Biosimilars Market by Product (Insulin, rhGH, Granulocyte colony-stimulating factor, Interferon, Erythropoietin, Etanercept, Monoclonal antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium), By Manufacturing (In-house, Contract) & Indication (Offsite Treatment, Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease, Blood Disorders, Infectious Disease, and Other Diseases), By Geography (North America, Europe, APAC, and RoW) Global Opportunity Analysis and Industry Forecast up to 2026

  • Report Code : IHR1910133
  • Published On: Apr, 2021
  • Category : Pharmaceuticals
  • Pages : 85
  • Biosimilars Market by Product (Insulin, rhGH, Granulocyte colony-stimulating factor, Interferon, Erythropoietin, Etanercept, Monoclonal antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium), By Manufacturing (In-house, Contract) & Indication (Offsite Treatment, Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease, Blood Disorders, Infectious Disease, and Other Diseases), By Geography (North America, Europe, APAC, and RoW) Global Opportunity Analysis and Industry Forecast up to 2026

    Biosimilars or follow-on-biologics are the "duplicated" and authorized variants of those reference biologics that have experienced patent expiration. Biosimilars improvement and approval with reference biologics is a significant part of the general advancement and development process. Guidelines for biosimilars assume an essential job in keeping up the suitability and harmony among unique and biosimilars items. Different regulatory specialists, for example, EMA and FDA effectively control Biosimilars commercialization and advancement.

    Research Methodology:

    The biosimilars market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology, along with an irreplaceable blend of primary insights. The real-time assessment of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary participants have helped in compiling relevant aspects with realistic parametric estimations for a comprehensive study. The participation share of different categories of primary participants is given below:

    The market is driven by factors such as the rising prevalence of chronic diseases such as cancer and diabetes supplement the growing demands of pharmaceutical drugs. However, market growth is limited by manufacturing complexities and resistance from biological manufacturers. Furthermore, the growth of the biosimilars market is hampered with multiple factors including the lack of regulatory guidelines, consumers’ brand preferences, the reluctance of physicians to prescribed biosimilars, and the high capital required for research and development.

    Based on the parameter of manufacturing, the market of Biosimilars is segmented into two segments:

    In-house manufacturing

    Contract manufacturing

    The in-house manufacturing segment makes up for the larger market share, while the contract manufacturing segment is expected to witness the highest CAGR during the forecasting period.

    Based on the product, the biosimilars market monoclonal antibody industry is prominently segmented into trastuzumab, infliximab, rituximab, adalimumab, and other monoclonal antibodies. The infliximab segment accounted for the largest biosimilars market share in 2019. The growing prevalence of autoimmune diseases drives market growth.

    Based on the indication, the market is segregated on the basis of:

    Oncology

    Blood Disorder

    Offsite Treatment

    Infectious Diseases

    Chronic Diseases

    Autoimmune Disease

    Other Diseases

    The oncology segment accounts for a major share of the biosimilars market. The large share of this segment can be attributed to the high incidence of cancer across the globe.

    Some of the major players in the domain of Biosimilars are Probiomed, Boehringer Ingelheim, Apotex, Fresenius Kabi, Gedeon Richter, Mabxience, Amega Biotech, Biocad, Coherus Biosciences, Stada Arzneimittel Ag, Dr. Reddy’s Laboratories, Mylan, Samsung Biologics, Amgen, Biocon, Celltrion, Teva Pharmaceutical, Eli Lilly, Pfizer, and Sandoz.

    By Geography, the market of Biosimilars is further classified into North America, Europe, the Asia Pacific, and the rest of the World. North America accounted for the largest share. There are two important factors which are the driving forces behind the growth of Biosimilars market giving it CAGR of 23.9% during the forecast period. These two factors are:

    Lower pricing than competing biologics

    Rising incidence of chronic diseases

    There are a lot of opportunities in emerging countries and this report will help in understanding the current market dynamics, changing needs, and innovations that might be needed to make the user experience enriching.

    This report would be the foundation for any research on the Biosimilars, vendor capabilities, SWOT of the sensors, and organized framework for data analysis for further advanced innovation.

    This piece of the report would be the backbone for exhaustive research and a tool for the upcoming innovations and technologies. This gives an idea about the major competitors in the market, their journey, and the competitive edge which one should have to beat other players in the market.

    The report is having a qualitative analysis of the Biosimilars market and the opportunity which can be leveraged by the market in the current scenario

    The market report would be delving into deep insights regarding the technological innovations

     

  • With tables and figures helping analyze worldwide Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

    Executive Summary
    Industry Outlook
    Industry Overview
    Industry Trends
    Market Snapshot
    Market Definition
    Market Outlook
    PEST Analysis
    Porter Five Forces
    Related Markets
    Market characteristics
    Market Evolution
    Market Trends and Impact
    Advantages/Disadvantages of Market
    Regulatory Impact
    Market Offerings
    Market Segmentation
    Market Dynamics
    Drivers
    Restraints
    Opportunities
    DRO - Impact Analysis
    Indication: Market Size & Analysis
    Overview
    Autoimmune Disease
    Blood Disorders
    Infectious Disease
    Chronic Disorder
    Oncology
    Offsite Treatment
    Other Diseases
    Type of Manufacturing: Market Size & Analysis
    Overview
    In-House Manufacturing
    Contract Manufacturing
    Product: Market Size & Analysis
    Overview
    Insulin
    Recombinant human growth hormone (rhGH)
    Granulocyte colony-stimulating factor
    Interferon
    Erythropoietin
    Etanercept
    Monoclonal antibodies
    Rituximab
    Infliximab
    Adalimumab
    Trastuzumab
    Follitropin
    Glucagon
    Calcitonin
    Teriparatide
    Enoxaparin Sodium
    Geography: Market Size & Analysis
    Overview
    North America
    Europe
    Asia Pacific
    Rest of the World
    Competitive Landscape
    Competitor Comparison Analysis
    Market Developments
    Mergers and Acquisitions, Legal, Awards, Partnerships
    Product Launches and execution
    Vendor Profiles
    Dr. Reddy’s Laboratories
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Stada Arzneimittel Ag
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Coherus Biosciences
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Biocad
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Amega Biotech
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Probiomed
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Boehringer Ingelheim
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Apotex
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Fresenius Kabi
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Gedeon Richter
    Overview
    Product Offerings
    Geographic Revenue
    Business Units
    Developments
    SWOT Analysis
    Business Strategy
    Companies to Watch
    Mabxience
    Overview
    Market
    Business Strategy
    Sandoz
    Overview
    Market
    Business Strategy
    Pfizer
    Overview
    Market
    Business Strategy
    Eli Lilly
    Overview
    Market
    Business Strategy
    Teva Pharmaceutical
    Overview
    Market
    Business Strategy
    Celltrion
    Overview
    Market
    Business Strategy
    Biocon
    Overview
    Market
    Business Strategy
    Amgen
    Overview
    Market
    Business Strategy
    Samsung Biologics
    Overview
    Market
    Business Strategy
    Mylan
    Overview
    Market
    Business Strategy
    Analyst Opinion
    Annexure
    Report Scope
    Market Definitions
    Research Methodology
    Data Collation and In-house Estimation
    Market Triangulation
    Forecasting
    Report Assumptions
    Declarations
    Stakeholders
    Abbreviations

     

  • The Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.

    Report Objectives / Segmentation Covered :
    By Companies / players:
      By Regions:
        By Type:
          By Application:
          Frequently asked questions(FAQ's):
          What is the major concern of the players in the Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating Market?

          As manufacturers prepare to scale up, Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating companies must be clear and transparent about the impact of such volatility on the balance sheet.

          What is the estimated size & growth rate of the Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating Market?

          In recent years, the Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating Market has grown at an incredible rate. From 2024 to 2029, the market is expected to grow at a CAGR of yy%.

          What does the future hold for the Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating Market?

          As the shift to value addition continues, companies in the Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating Market face the dual challenge of improving interoperability to optimize performance and experience.

          How does the Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating Market study reflects the current scenario?

          The Biosimilars Market by Product (Insulin rhGH Granulocyte colony stimulating study focuses on shifting market dynamics, geopolitical and regulatory regulations, and key players' strategies to carefully analyze demand at risk across multiple industry categories.

          Our Clients